ArticleSurgical endoscopy2025
Medication cost for treatment of metabolic dysregulation decreases following adolescent bariatric surgery.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe burden of obesity-related metabolic dysfunction in adolescents is skyrocketing; the purpose of this study is to understand the impact of adolescent bariatric surgery on the utilization and cost of medications for treatment of metabolic dysregulation.
methodsUsing the MarketScan database of commercial health insurance claims from 2011-2019, bariatric surgery patients ages 14-18 (n = 992) were assessed for patterns of medication utilization pre-surgery (beginning of MarketScan enrollment to 6 months before surgery) and post-surgery (> 12 months after surgery). We examined the cost and rate of prescription fills for diabetes, cardiovascular, and dyslipidemia medications. We calculated standardized utilization rates and ran generalized estimating equations for utilization and cost of each medication with Poisson distribution to test for differences at the various time intervals. We also compared utilization and cost for the surgical patients two three control groups, stratified based on body mass index.
resultsUtilization of diabetes and dyslipidemia medications showed a significant decrease in the incidence rate ratio (95% confidence interval) for the post-surgery period relative to the pre-surgery period (0.428 (0.223-0.82) p = 0.01; 0.194 (0.056-0.667) p < 0.01). The total annual cost for the entire cohort of bariatric surgery patients (95% confidence interval) also decreased after surgery with dyslipidemia medications decreasing by $8,666.11 ($1011.84-$16,308.48), cardiovascular medications decreasing by $33,890.68 ($14,403.84-$53,389.44) and diabetes medications decreasing by $45,949.44 ($3,083.14-$94,993.92).
conclusionFollowing adolescent bariatric surgery, there is a decrease in utilization of diabetes and dyslipidemia medications. There was decreased cost for diabetes, dyslipidemia, and cardiovascular medications. These results suggest that performing bariatric surgery during late adolescence is associated with overall improvements in metabolic health.
Indexed as
Identifiers
40571792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.